Evidence map›Paper›PMID 32551117›Full record

ArticleSAGE open medical case reports2020

Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis.

Remiko Kobayashi, Yasunori Oda, Ryunosuke Hayatsu, Nozomi Ohki, Misa Akutsu, Takahiro Oiwa, Hideki Komatsu, Tomihisa Niitsu, Tsuyoshi Sasaki, Masaomi Iyo

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Remiko KobayashiDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yasunori OdaDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-4957-5847
Ryunosuke HayatsuDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Nozomi OhkiDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Misa AkutsuDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takahiro OiwaDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hideki KomatsuDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tomihisa NiitsuDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tsuyoshi SasakiDepartment of Child Psychiatry, Chiba University Hospital, Chiba, Japan.
Masaomi IyoDepartment of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPChiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the case of a 49-year-old Japanese male patient successfully treated with a paliperidone rechallenge following 2-year treatment with clozapine for treatment-resistant schizophrenia. He had responded well to conventional antipsychotic treatment for the initial psychotic episode but gradually developed dopamine supersensitivity; even treatment with paliperidone and another antipsychotic medication (a total up to 1700 mg in chlorpromazine-equivalent dose) had not improved his psychotic symptoms. Clozapine treatment produced temporary symptomatic relief, but the clozapine dose could not be increased to > 150 mg due to the patient's intolerance. Following low-dose clozapine treatment for 2 years, a rechallenge with paliperidone monotherapy ameliorated his psychotic symptoms. This suggests that clozapine may have the potential to release the dopamine supersensitivity state. Our patient's case indicates that for patients with dopamine supersensitivity psychosis, a rechallenge with a previously ineffective antipsychotic after clozapine treatment may be successful.

Indexed as

clozapinedopamine D2 receptorDopamine supersensitivity psychosispaliperidonetreatment-resistant schizophrenia

Identifiers

PMID32551117
PMCPMC7278325
OpenAlexW3033718219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.